Insilico Medicine
-
Insilico Medicine signs US$2.5B strategic alliance with CDMO Bora Pharmaceuticals
The multi-target collaboration will integrate Insilico’s proprietary Pharma.AI platform with Bora’s automated manufacturing and development capabilities to establish a next-generation model for drug innovation.
-
Insilico Medicine signs strategic US$600M AI drug discovery agreement with Takeda
Under the collaboration, Insilico Medicine will use its proprietary Pharma.AI platform to identify and optimise drug candidates that meet predefined scientific and early development criteria.
-
Insilico Medicine unveils UAE’s first fully AI-discovered cancer drug candidate
AI Platform Accelerates Development Timeline
The team developed ISM0387 using Insilico Medicine’s Chemistry42 platform, which integrates more than 40 generative AI models to analyse complex biological and chemical data. -
AI drug developer Insilico Medicine secures US10M deal for Parkinson’s treatment
Insilico will lead the initial phase, advancing ISM8969 through preclinical studies and into a phase 1 clinical trial for Parkinson’s disease.